CDDO-EA, or 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide, is a synthetic triterpenoid compound known for its potential therapeutic properties. It is derived from oleanolic acid and is recognized for its anti-inflammatory, antioxidant, and anticancer activities. CDDO-EA functions primarily through the activation of the Nrf2 pathway, which plays a crucial role in cellular defense mechanisms against oxidative stress. This compound exhibits a range of biological effects, including the inhibition of cell proliferation and induction of apoptosis in various cancer cell lines. Additionally, CDDO-EA has been studied for its potential in treating conditions such as neurodegenerative diseases and metabolic disorders. Its solubility and stability in biological systems make it a subject of interest in pharmacological research. However, further studies are necessary to fully elucidate its mechanisms of action and therapeutic efficacy in clinical settings. As with many experimental compounds, safety and dosage considerations are critical for its potential application in medicine.

CDDO-EA

932730-51-3: CDDO-EA, or 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide, is a synthetic triterpenoid compound known for its potential therapeutic properties. It is derived from oleanolic acid and is recognized for its anti-inflammatory, antioxidant, and anticancer activities. CDDO-EA functions primarily through the activation of the Nrf2 pathway, which plays a crucial role in cellular defense mechanisms against oxidative stress. This compound exhibits a range of biological effects, including the inhibition of cell proliferation and induction of apoptosis in various cancer cell lines. Additionally, CDDO-EA has been studied for its potential in treating conditions such as neurodegenerative diseases and metabolic disorders. Its solubility and stability in biological systems make it a subject of interest in pharmacological research. However, further studies are necessary to fully elucidate its mechanisms of action and therapeutic efficacy in clinical settings. As with many experimental compounds, safety and dosage considerations are critical for its potential application in medicine.

<p>CDDO-EA (CDDO ethyl amide) is an activator of the Nrf2/antioxidant response element.</p>

CAS 932730-51-3

CDDO-EA

CDDO-EA

Ref: 54-BUP02423

CDDO-EA

Ref: TM-T10733